SRR8613786
— · C
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- C
- subtype
- C
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.410
- G2M_CHECKPOINT+0.340
- PROTEIN_SECRETION+0.320
- GLYCOLYSIS+0.300
- ESTROGEN_RESPONSE_LATE+0.290
- MITOTIC_SPINDLE+0.260
- PI3K_AKT_MTOR_SIGNALING+0.260
- TGF_BETA_SIGNALING+0.220
- MTORC1_SIGNALING+0.190
- UV_RESPONSE_DN+0.180
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.380
- OXIDATIVE_PHOSPHORYLATION-0.270
- INTERFERON_GAMMA_RESPONSE-0.260
- MYC_TARGETS_V2-0.260
- ADIPOGENESIS-0.180
- ANGIOGENESIS-0.150
- COMPLEMENT-0.150
- PANCREAS_BETA_CELLS-0.150
- TNFA_SIGNALING_VIA_NFKB-0.150
- BILE_ACID_METABOLISM-0.130
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | ERR2278878 | — | — | 0.747 |
| 2 | TCGA-FD-A3B5-01A-11R-A20F-07 | — | — | 0.714 |
| 3 | MNG1076 | — | — | 0.712 |
| 4 | SRR1313121 | — | B | 0.712 |
| 5 | TCGA-FD-A5C0-01A-11R-A28M-07 | — | — | 0.681 |
| 6 | SRR15069611 | — | — | 0.678 |
| 7 | a82c207a-ac59-48cf-9bbf-13ff024e3f95 | — | — | 0.671 |
| 8 | SRR27320684 | — | — | 0.671 |
| 9 | TCGA-A2-A0YJ-01A-11R-A109-07 | — | E | 0.671 |
| 10 | MNG1062 | — | — | 0.667 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.410 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.340 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.320 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.300 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.290 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.260 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.260 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.220 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.190 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.180 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.170 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.170 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.160 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.160 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.140 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.140 | Inavolisib | — uncovered |
| HYPOXIA | 0.130 | Idelalisib | — uncovered |
| PEROXISOME | 0.120 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.120 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.100 | Idelalisib | — uncovered |